Name: Itacitinib (INCB39110)
Brand: Selleck Chemicals
SKU: S7812
Availability: InStock
Rating: 5 (12 reviews)

Jump to

Quality Control

Batch: Purity: 99.99%

99.99

Related Targets	EGFR STAT Pim
Other JAK Inhibitors	BMS-986165 (Deucravacitinib) AZD1480 WP1066 Filgotinib (GLPG0634) Momelotinib (CYT387) AT9283 Gandotinib (LY2784544) Pacritinib (SB1518) NVP-BSK805 2HCl TG101209

Solubility

In vitro
Batch:

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	10%DMSO 1 40%PEG300 2 5%Tween80 3 45%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	6.000mg/ml (10.84mM)	Taking the 1 mL working solution as an example, add 100 μL of 60 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to make it clear; then continue to add 450 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	553.51	Formula	C₂₆H₂₃F₄N₉O	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	1334298-90-6	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			SMILES	C1CN(CCC1N2CC(C2)(CC#N)N3C=C(C=N3)C4=C5C=CNC5=NC=N4)C(=O)C6=C(C(=NC=C6)C(F)(F)F)F

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	JAK1
In vitro	INCB039110 is a potent and selective inhibitor of JAK1, with >20 and >200-fold selectivity over JAK2 and JAK3, respectively. The activity against JAK1, 2, 3, and TYK2 are 2, 63, >2000, and 795 nM, respectively.
In vivo	INCB039110 blocks tumor growth in human pancreatic xenograft models in mice at clinically relevant doses, both as monotherapy and in combination with cytotoxic agents.
References	[1] https://pubmed.ncbi.nlm.nih.gov/27774824/ [2] http://cancerres.aacrjournals.org/content/75/15_Supplement/779 [3] https://pubmed.ncbi.nlm.nih.gov/32562787/ [4] https://pubmed.ncbi.nlm.nih.gov/35571736/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2025-09-18)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05823571	ACTIVE_NOT_RECRUITING	Leukemia, Acute; Myelodysplastic Syndromes; Myelomonocytic Leukemia, Chronic; T-cell Prolymphocytic Leukemia; CML; Myeloproliferative Disorders; Multiple Myeloma; Plasma Cell Leukemia	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	2023-07-06	PHASE1
NCT04061421	RECRUITING	MDS/MPN	Michael Savona	2021-11-24	PHASE1; PHASE2
NCT04859946	ACTIVE_NOT_RECRUITING	Hematologic and Lymphocytic Disorder	M.D. Anderson Cancer Center	2022-01-11	PHASE2
NCT05364762	ACTIVE_NOT_RECRUITING	Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia; Myelodysplastic Syndrome; Myeloproliferative Neoplasm; Primary Myelofibrosis; Secondary Myelofibrosis	City of Hope Medical Center	2022-11-23	PHASE2
NCT04509700	ACTIVE_NOT_RECRUITING	B-Cell Malignancies	Incyte Corporation	2020-08-03	PHASE2
NCT05757219	RECRUITING	Diffuse Large B Cell Lymphoma	H. Lee Moffitt Cancer Center and Research Institute	2023-05-19	PHASE2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Itacitinib (INCB39110) JAK1 Inhibitor

Chemical Structure

Molecular Weight: 553.51